



## Northern Care Alliance Foundation Trust and CSL Collaborative Working Summary

<b>Project title</b>	Northern Care Alliance NHS Foundation Trust Medicines Initiation & Optimisation Clinic for Glomerulonephritis (GN) Collaborative Working Project
<b>Brief Project Summary</b>	<p>This project will implement and evaluate a consultant-led pharmacist-delivered GN clinic for patients with glomerulonephritis within the established Salford Complex GN service. Stratifying patients to set pathways will free up consultant time to see more complex patients. The pharmacist will deliver a clinic to offer structured education, therapy initiation and monitoring aligned with National Institute for Health and Care Excellence (NICE) guidance and Kidney Disease: Improving Global Outcomes (KDIGO<sup>1</sup>) principles, supported by consultant nephrologist oversight and multidisciplinary review.</p> <p>The project aims to:</p> <ol style="list-style-type: none"><li>1) Set up a new consultant-led pharmacist-delivered GN weekly clinic</li><li>2) Improve equitable access to and appropriateness of high-cost therapies</li><li>3) Enhance adherence to medication and patient experience</li><li>4) Capture and analyse data to demonstrate how the new service delivers better kidney outcomes while using resources more efficiently.</li><li>5) Improve the education of healthcare professionals by sharing project outputs with 2 other regional centres and a national meeting</li><li>6) Preparation of manuscript for a peer reviewed journal to share impact of service outcomes</li></ol>
<b>Project objectives</b>	<p><b>NHS</b></p> <ul style="list-style-type: none"><li>• Standardised therapy drug education, initiation and optimisation for IgAN (e.g. budesonide and sparsentan) using protocol driven, pharmacist led pathways</li><li>• Generate real world evidence on clinical effectiveness and patient reported outcomes in the new clinic service</li><li>• Support commissioning, affordability and proof of sustainability by aligning with NHS England high-cost drug processes and Blueteq prior approval where applicable</li><li>• Undertake a health economic analysis of the clinic and outcomes (e.g. consultant vs pharmacy clinic, healthcare</li></ul>

	<p>utilisation (admissions), requirement of dialysis and transplantation).</p> <ul style="list-style-type: none"> <li>• Increase clinic capacity by stratifying patients to appropriate health care provider.</li> </ul> <p><b>Patient</b></p> <ul style="list-style-type: none"> <li>• Embed NICE medicines optimisation and shared decision-making principles, including medication review.</li> <li>• Ensure equitable access through inclusive eligibility, proactive case finding and measure uptake by sex and ethnicity</li> <li>• Stratify existing patients to set treatment pathways thereby freeing up consultant time to see more complex GN patients</li> <li>• Provision of care closer to home by option of telephone clinic</li> </ul> <p><b>Industry</b></p> <ul style="list-style-type: none"> <li>• Real world evidence generation of clinical implementation and adherence to guidelines and measurement of patient reported experience</li> <li>• Timely access to medications in line with NICE TA implementation</li> <li>• Enhanced experience of partnering with NHS organisations</li> </ul>
<b>Project period</b>	Feb 2026 – April 2027
<b>References</b>	<ol style="list-style-type: none"> <li>1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney Int.</i> 2021;100(4S):S1–S276.</li> </ol>